116 related articles for article (PubMed ID: 9265263)
1. [Does tamoxifen have a negative effect on survival chances of premenopausal women with locoregional recurrence of breast carcinoma?].
Sauer H
Strahlenther Onkol; 1997 Jul; 173(7):390. PubMed ID: 9265263
[No Abstract] [Full Text] [Related]
2. Possible deleterious effect of tamoxifen in premenopausal women with locoregional recurrence of breast cancer.
Borner MM; Bacchi M; Castiglione M
Eur J Cancer; 1996 Nov; 32A(12):2173-6. PubMed ID: 9014762
[TBL] [Abstract][Full Text] [Related]
3. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
4. Exacerbation of endometriosis as a result of premenopausal tamoxifen exposure.
Rose PG; Alvarez B; Maclennan GT
Am J Obstet Gynecol; 2000 Aug; 183(2):507-8. PubMed ID: 10942499
[TBL] [Abstract][Full Text] [Related]
5. Caring for the breast cancer survivor.
Abdel-Razeq H
Am J Med; 2011 Feb; 124(2):e11; author reply e13. PubMed ID: 21295181
[No Abstract] [Full Text] [Related]
6. New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer.
Rosenberg SM; Partridge AH
J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26307642
[No Abstract] [Full Text] [Related]
7. Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen.
Abad de Velasco L; Cano A
Eur J Obstet Gynecol Reprod Biol; 2003 Aug; 109(2):234-5. PubMed ID: 12860350
[TBL] [Abstract][Full Text] [Related]
8. Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer.
Sohn G; Ahn SH; Kim HJ; Son BH; Lee JW; Ko BS; Lee Y; Lee SB; Baek S
Cancer Res Treat; 2016 Oct; 48(4):1351-1362. PubMed ID: 27063654
[TBL] [Abstract][Full Text] [Related]
9. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
10. Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women.
Parton M; Smith IE
J Clin Oncol; 2008 Feb; 26(5):745-52. PubMed ID: 18258982
[No Abstract] [Full Text] [Related]
11. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
12. Feature of amenorrhea in postoperative tamoxifen users with breast cancer.
Kim H; Han W; Ku SY; Suh CS; Kim SH; Choi YM
J Gynecol Oncol; 2017 Mar; 28(2):e10. PubMed ID: 27894163
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
[TBL] [Abstract][Full Text] [Related]
14. Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.
Strasser-Weippl K; Badovinac-Crnjevic T; Fan L; Goss PE
Breast; 2013 Aug; 22 Suppl 2():S171-5. PubMed ID: 24074782
[TBL] [Abstract][Full Text] [Related]
15. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
[TBL] [Abstract][Full Text] [Related]
16. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
[TBL] [Abstract][Full Text] [Related]
17. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
Tormey DC; Gray R; Falkson HC
J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
[TBL] [Abstract][Full Text] [Related]
18. Beware of amenorrhea during tamoxifen: it may be a wolf in sheep's clothing.
Mourits MJ; de Vries EG; ten Hoor KA; van der Zee AG; Willemse PH
J Clin Oncol; 2007 Aug; 25(24):3787-8; author reply 3788-9. PubMed ID: 17704431
[No Abstract] [Full Text] [Related]
19. [Tamoxifen; wider indications, more frequent controls?].
Rutgers EJ; Nortier JW; Beex I;
Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1766-7. PubMed ID: 11589197
[No Abstract] [Full Text] [Related]
20. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.
Fowble B; Fein DA; Hanlon AL; Eisenberg BL; Hoffman JP; Sigurdson ER; Daly MB; Goldstein LJ
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):669-77. PubMed ID: 8690632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
